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Abstract
Natural killer cells have been demonstrated to play a major role in mediating an anti-leukemia effect
in patients given a T-cell depleted allogeneic hematopoietic stem cell transplantation from an HLA-
haploidentical family donor. In particular, donor-derived natural killer cells, which are alloreactive
(i.e. KIR/HLA mismatched) towards recipient cells, significantly contribute to the eradication of
leukemia blasts escaping the preparative regimen to transplantation. A recent study on high-risk
pediatric acute lymphoblastic leukemia refractory to chemotherapy further highlighted the
importance of donors with alloreactive natural killer cells in haploidentical hematopoietic stem cell
transplantation, as it demonstrated that these cells can emerge starting from the fourth-fifth month
after the allograft and persist for many months. This study represents a major breakthrough in the
cure of otherwise fatal leukemias, providing information on the best criteria for choosing the
optimal donor.
Allogeneic haematopoietic stem cell transplantation
(allo-HSCT) is largely employed for treating paediatric
patients affected by many haematological conditions of
both malignant and non-malignant origin, as well as by
several hereditary disorders of the immune system and
metabolism [1,2]. More than 40 years have elapsed since
the first successful allo-HSCT, then performed using bone
marrow (BM) cells [3,4], and through this procedure
thousands of children have been cured of their original
disease [1,2].
All this long history has taught that the success of allo-
HSCT is strictly dependent on the balance between the
detrimental, sometimes fatal, attack of donor immune
cells against recipient tissues (i.e. graft-versus-host dis-
ease, GVHD) and the favourable reaction of donor lym-
phocytes towards malignant cells (i.e. graft-versus-tumor,
GVT, effect) and/or pathogens capable of causing life-
threatening infections during the period of profound neu-
tropenia and lymphopenia which follows the condition-
ing regimen. While in the context of classical allo-HSCT
from an HLA-identical sibling large part of the GVT effect
is related to the attack of donor T lymphocytes against
non-shared minor histocompatibility antigens expressed
on tumor cells, there is clear evidence that also a selective
effect of donor innate immunity (i.e. not dependent from
previous encounter with the antigen) can contribute to
the eradication of the malignant clone [5]. The role played
by the donor innate immunity has attracted the interest of
the scientific community only in recent years, when signif-
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icant advances in the use of allo-HSCT have occurred. In
particular, while for many years an HLA-matched sibling
was the only type of donor routinely employed, in the last
decade, matched unrelated volunteers and unrelated
umbilical cord blood (UCB) units are being largely uti-
lized to transplant patients lacking an HLA-identical rela-
tive [6]. The most recent, and advanced, frontier of allo-
HSCT is represented by transplantation from an HLA-par-
tially matched relative and, in this very context, the contri-
bution of donor innate immunity to the success of the
procedure has become evident. Indeed, in order to per-
form transplantation from an HLA-disparate donor, it is
mandatory to remove from the allograft donor T cells,
which, otherwise, could attack recipient-specific, either
major (in large part) or minor histocompatibility, anti-
gens, this resulting in extremely severe, often fatal, GVHD
[6]. The removal of T lymphocytes, coupled with the infu-
sion of high-doses of haematopoietic progenitors, col-
lected from donor peripheral blood after mobilization
with cytokines, has rendered possible what for many years
was considered a sort of holy grail, namely the engraftment
of donor haematopoiesis across the HLA barrier, without
leading to the development of GVHD [7,8]. However, in
view of the role played by donor T cells in mediating the
GVT effect, it could be expected that a relevant proportion
of patients given this type of allograft experience leukae-
mia recurrence. This expectation was only partly con-
firmed by the clinical results, as it became evident, mainly
in adult patients affected by acute myeloid leukaemia
(AML), that there was a subgroup of patients given T-cell
depleted allo-HSCT from an HLA-disparate relative who
had a particularly low risk of leukaemia relapse [9]. These
patients belonged to the group transplanted from a donor
having natural killer cells (NK) that are alloreactive
towards recipient targets. This concept of NK-cell alloreac-
tivity has represented a sort of revolution in the field of
allo-HSCT, underlining for the first time that not only
adaptive immunity, but also innate immunity is a crucial
element for guaranteeing a successful patient's outcome.
NK cells are key members of the natural immune system,
which each single individual possesses, and are of funda-
mental importance to limit or eradicate pathogens during
the early phases of a primary infection, i.e. before T and B
cells can mount efficient responses [5,10]. Indeed, NK
cells and phagocytes do not require clonal expansion and
can enter and defend a tissue almost as soon as it becomes
infected. NK cells, derived from the haematopoietic pro-
genitors through a common lymphoid progenitor [10],
play a pivotal role in the defense against viral infections
and transformed cells. The molecular mechanisms that
allow NK cells to spare normal cells and kill tumor or
virus-infected cells are represented by the interplay
between an array of surface receptors with either activat-
ing or inhibitory function [5,10]. Indeed, NK-cell func-
tion results from the net balance between activatory and
inhibitory signals (see also Figure 1). The role played by
inhibitory signals represents a peculiarity of NK cells in
comparison to the function of both T and B lymphocytes
which is regulated only by activatory signals, and the sig-
nals delivered by inhibitory receptors present on the sur-
face of NK lymphocytes are even more important than the
activatory signals [5,10,11]. NK receptors are known as
Killer Immunoglobulin-like receptors (KIR), and the
inhibitory ones specifically interact with determinants
that are shared by different HLA-class I molecules
(referred to as KIR ligands). In a self environment, to
ensure self tolerance, each individual NK cell expresses at
least one inhibitory receptor specific for autologous HLA-
class I and an NK-mediated attack towards autologous
cells occurs only when these do not express at all or
express low amounts of HLA class-I molecules.
In an allogeneic setting, NK cells can kill non-self cells and
the molecular basis for NK alloreactivity also involves NK-
cell KIR inhibitory receptors that are specific for determi-
nants that are shared by different KIR ligands (i.e. HLA-
class I alleles). In detail, KIR2DL1 recognizes HLA-C alle-
les characterized by Lys at position 80 (HLA-CLys80, also
named C2 group), KIR2DL2/3 recognize HLA-C alleles
characterized by Asn at position 80 (HLA-CAsn80, C1
group), KIR3DL1 recognizes HLA-B alleles sharing the
Bw4 supertypic specificity (HLA-BBw4, Bw4 group) [12].
This kind of inhibitory KIR receptor repertoire can lead to
alloreactivity in haplo-HSCT through the mechanism of
"missing self" recognition [13], provided that the donor:
i) expresses a KIR-ligand which is missing in the recipient
HLA genotype; and ii) expresses the specific KIR, leading
to a KIR/KIR-ligand mismatch in graft-versus-host (GvH)
direction. In other words, NK alloreactivity can be pre-
dicted to occur when analysis of the HLA-class I genotypes
reveals that a KIR ligand is expressed in the donor but is
missing in the recipient (KIR ligand-mismatch).
The existence of human "alloreactive" NK cells was origi-
nally suggested two decades ago by the hybrid resistance
phenomenon in which NK cells proved to be responsible
for the rejection of parental bone marrow grafts in F1
hybrid mice [14]. However, the clinical relevance of the
corresponding phenomenon in human beings was not
recognized till the emergence of results in adults given
haplo-HSCT, demonstrating the reduction in the risk of
leukaemia recurrence observed when the donor showed
an NK alloreactivity with respect to the recipient HLA typ-
ing [15]. This striking finding significantly changed the
criteria for choosing the HSCT donor in the context of T-
cell depleted allograft from an HLA-disparate relative.
One of the most intriguing clinical questions related to
donor NK alloreactivity involves the observation that thisItalian Journal of Pediatrics 2009, 35:44 http://www.ijponline.net/content/35/1/44
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peculiar GVT effect is completely separated by the occur-
rence of GVHD, this indicating that NK cells are able to
kill leukaemia targets, while sparing normal tissues.
Clearly, the selectivity of the GVT effect displayed by NK
cells cannot be attributed to an attack directed against
antigens with a restricted expression on tumor cells, as the
ligands of NK-cell KIR inhibitory receptors are, as men-
tioned above, determinants of HLA-class I molecules
which are expressed on all nucleated cells of the body.
Thus, the preferential lysis of tumor cells by NK lym-
phocytes can be interpreted only in view of the role played
by activatory signals. Indeed, there is large experimental
evidence that killing of allogeneic cells also depends on
the surface density of activating receptors on NK cells and
on the expression of their ligands on target cells [16,17].
It is currently accepted that leukaemia targets express on
their cell surface ligands able to efficiently engage activa-
tory KIR receptors [18]. Support to this interpretation is
provided by the observation that, in the animal model,
alloreactive NK cells not only lyse leukaemia blasts, but
also kill recipient dendritic cells (DC) and T lymphocytes
[10], all these targets belonging to cells deriving from the
haematopoietic tissue, which, evidently, has a particular
capacity to render NK cells efficiently active. This biologi-
cal observation translates into other two relevant clinical
advantages, namely prevention of GVHD, whose occur-
rence is certainly facilitated by the role played by recipient
DC [19], and prevention of graft rejection, which is a com-
plication mainly due to the effect of recipient cytotoxic T
lymphocytes surviving the preparative regimen (see also
Figure 2 for details).
If the relevance of NK alloreactivity has been demon-
strated in the setting of adult myeloid leukaemia, one
could argue which is the interest of this phenomenon for
paediatricians. The answer comes from recent results that
Schematic representation of the main interactions occurring between normal natural killer (NK) cells (expressing both HLA  class I-specific inhibitory receptors and activating receptors) and potential target cells Figure 1
Schematic representation of the main interactions occurring between normal natural killer (NK) cells 
(expressing both HLA class I-specific inhibitory receptors and activating receptors) and potential target cells. 
Normal tissues deliver inhibitory signals, which block NK cells (a). Normal stressed tissues deliver simultaneously both activa-
tory and inhibitory signals, this also resulting in block of the lytic capacity of NK cells (b). The lack of inhibitory signals, by con-
trast, permits NK cells to kill their targets, activatory signals playing a facilitating role (c). Modified from Moretta et al. 
Immunology Today 2004.
Modified from Moretta et al, 2004
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our groups have obtained [12]. In fact, we have demon-
strated that the favourable effect mediated by donor NK
alloreactivity is of crucial relevance in paediatric patients
with acute lymphoblastic leukaemia (ALL), which, by far,
represents the most common malignancy of childhood.
In a study involving 21 children transplanted from an NK-
alloreactive parent, we have documented that NK cells of
donor origin able to kill leukaemia blasts emerge since the
4-5th month after the allograft, persist for years and signif-
icantly contribute to the eradication of the malignant
clone [12]. These results emphasize the concept that the
role of innate immunity in allo-HSCT must be completely
revised and re-considered also by pediatricians and, once
again, demonstrated that what has been obtained in
adults (namely an NK effect in AML, but not in ALL) can-
not automatically be translated to children, this finding
being in keeping with the old aphorism that a child is not
an adult in miniature.
Is the mechanisms of NK alloreactivity in childhood leu-
kaemia completely understood and the role of NK cells in
transplantation fully defined? The answer is obviously no.
Indeed, it remains to be addressed the unsolved problem
of the need of an efficient NK alloreactive effect also in the
first months after the allograft. Isolation of mature donor
NK cells and their proper activation with specifically
active cytokines, such as interleukin-15, could be the right
solution for filling this gap and further ameliorating the
clinical results of haplo-HSCT in childhood ALL. Many
other biological and clinical issues also deserve critical
attention for the future. Among them, the observation
that, in the presence of the same kind of NK alloreactivity,
Donor-derived alloreactive NK cells are able to kill leukaemia targets (this preventing disease recurrence), dendritic cells (DC)  of the recipient (this preventing graft-versus-host disease recurrence) and cytotoxic T-lymphocytes of the recipient (this pre- venting graft rejection) Figure 2
Donor-derived alloreactive NK cells are able to kill leukaemia targets (this preventing disease recurrence), 
dendritic cells (DC) of the recipient (this preventing graft-versus-host disease recurrence) and cytotoxic T-
lymphocytes of the recipient (this preventing graft rejection). Modified from Ruggeri et al. Science 2002.
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mothers are better donors than fathers [20]. So far, we do
not precisely know the biological explanation of this find-
ing. What we can certainly conclude is that, also in the
field of transplantation of haematopoietic progenitors,
what happens during pregnancy matters.....
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